checkAd

     163  0 Kommentare Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock - Seite 3

    Investor Contact:
    Leiv Lea
    Chief Financial Officer
    Corvus Pharmaceuticals, Inc.
    +1-650-900-4522
    llea@corvuspharma.com

    Lesen Sie auch

    Media Contact:
    Sheryl Seapy
    W2O pure
    +1-213-262-9390
    sseapy@purecommunications.com



    globenewswire
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors

    Seite 3 von 3

    Verfasst von globenewswire
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    Corvus Pharmaceuticals Announces Pricing of Public Offering of Common Stock - Seite 3 BURLINGAME, Calif., Feb. 12, 2021 (GLOBE NEWSWIRE) - Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 8,571,429 shares of its common stock at …